Evidence map›Paper›PMID 39810030›Full record

ArticleObesity surgery2025

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Utilization and Association with Bariatric Surgery Outcomes.

Qais AbuHasan, Luke M Funk, Jane L Holl, Claire Draucker, Shaun Grannis, Karl Y Bilimoria, Dimitrios Stefanidis, Tarik K Yuce

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qais AbuHasanSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. qabuhas@iu.edu.
Luke M FunkDepartment of Surgery, University of Wisconsin, Madison, WI, USA.
Jane L HollSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Claire DrauckerIndiana University School of Nursing, Indianapolis, IN, USA.
Shaun GrannisThe Regenstrief Institute, Indianapolis, IN, USA.
Karl Y BilimoriaSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Dimitrios StefanidisSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Tarik K YuceSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. tyuce@iu.edu.

Funding

CTSA K12 Program at Indiana UniversityK12TR004415 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$971k
NCATS NIH HHS K12 TR004415
6 · The paper itself

Abstract

backgroundThe efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) for the treatment of obesity has led to considerably increased demand for these medications. GLP1RA use prior to bariatric surgery may represent a novel approach to treating obesity. The objectives of this study were to (1) describe trends in pre-bariatric GLP1RA use, (2) investigate social and clinical factors associated with their use, and (3) evaluate differences in clinical outcomes based on preoperative GLP1RA use.

methodsPatients who underwent bariatric surgery at three Indiana hospitals from 2018 to 2023 were identified. Patients who utilized GLP1RA in the year preceding surgery were compared to those who did not. Social factors included insurance, income, and unemployment. Outcomes included rates of GLP1RA use, 30-day postoperative readmissions, ED visits, and percent total weight lost (%TWL) at 1 year. Associations between preoperative GLP1RA use and outcomes of interest were evaluated using multivariable logistic and linear regressions.

resultsOf 2169 patients who underwent surgery, 293 (13.5%) utilized GLP1RA preoperatively. The rate of GLP1RA utilization increased threefold from 2018 to 2023. Males were more likely to receive preoperative GLP1RA (20.1% vs, 12.2%, p<0.001). There were no significant differences in social determinants of health or 30-day postoperative outcomes between patients who did and did not use GLP1RA preoperatively. Similarly, there were no significant differences in %TWL at 1 year postoperatively between groups (median 25.5% vs. 27.3%, coefficient, -0.78, 95%CI, -2.26 to 0.70).

conclusionsUtilization of GLP1RA in the year prior to bariatric surgery has increased threefold. Preoperative GLP1RA use is not associated with worse 30-day outcomes or differences in %TWL at 1 year postoperatively. Further work is needed to evaluate whether GLP1RA dosing and duration of treatment impact postoperative outcomes.

Indexed as

Bariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsObesity, MorbidPreoperative CareAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeWeight LossGlucagon-Like Peptide-1 Receptor AgonistsBariatric surgeryDisparitiesGLP1 agonistsOutcomes

Identifiers

PMID39810030
PMCPMC11835518

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.